All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2024-10-01T10:17:17.000Z

#SOHO2024: Hodgkin lymphoma and T-cell lymphoma

By Abhilasha Verma
Oct 1, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma.

Bookmark this article

To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up on our live social media coverage relating to Hodgkin lymphoma and T-cell lymphoma below.

More about...
Hodgkin lymphomaMature T and NK cell neoplasmsPeripheral T-cell lymphomaSOHO 2024

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
76 votes - 4 days left ...

Related articles

Add bookmark

The effect of COVID-19 on the management of patients with lymphoma

A summary of recommendations for patients with lymphoma during the COVID-19 pandemic provided by Executive Steering Committee Member Stefano Luminari.

Mar 24, 2020
Add bookmark

The effect of COVID-19 on the management of patients with lymphoma

A summary of recommendations for patients with lymphoma during the COVID-19 pandemic provided by Executive Steering Committee Member...

Mar 24, 2020
Add bookmark

ASCO 2019 | Allo-SCT versus Auto-SCT as first-line consolidation in PTCL (AATT study)

This trial compared the efficacy of allogeneic stem cell transplantation (allo-SCT) to autologous stem cell transplantation (Auto-SCT), as first line consolidation...

Jun 7, 2019
Add bookmark

ASCO 2019 | Allo-SCT versus Auto-SCT as first-line consolidation in PTCL (AATT study)

This trial compared the efficacy of allogeneic stem cell transplantation (allo-SCT) to autologous stem cell...

Jun 7, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox